Clinical trials: Moderate Depression
Depression
The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder
This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.
- Trial name
- NCT04720040
- Testing
- Mind STIM
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Ybrain Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder…
- Trial name
- VENTURA-7 (NCT06514742)
- Testing
- Aticaprant
- Where
- 84 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Mood
The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention
The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.
- Trial name
- NCT05318456
- Testing
- MoodElite T-4003-1, Comparator
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Chenland Nutritionals Inc.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Depression, Teen
Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents
The purpose of the present randomized controlled study is to investigate if there is a difference in depression symptoms at 4-weeks among adolescents ages 16-17 years assigned to W-GenZD, a digital therapeutic, as compared to a…
- Trial name
- NCT04985331
- Testing
- W-GenZD
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Woebot Health
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Depression, Post-COVID-19 Syndrome
Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
Clinical depression is a mood disorder that affects people of all ages with symptoms such as sadness, anger or frustration, appetite changes, difficulty concentrating and suicidal thoughts.
- Conditions
- Depression, Post-COVID-19 Syndrome, Depression Mild, Depression Moderate
- Trial name
- NCT06496087
- Testing
- DEPREXIL
- Where
- Colombia
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Depressive Disorder, Major
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency
The purpose of the study is to describe the clinical outcomes (severity of depression, severity of suicidality \& frequency of suicidal thinking, suicide events) and quality of life (QoL) of participants with symptoms of major…
- Trial name
- POWER (NCT04829669)
- Sponsor
- Janssen-Cilag Ltd.
Depressive Disorder, Major
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
- Trial name
- NCT00048204
- Testing
- GW597599B, paroxetine
- Volunteers
- 372 people
- Sponsor
- GlaxoSmithKline
Depression
Nexalin Therapy for the Treatment of Depressive Symptoms
The primary objectives of this Phase II study are to demonstrate the safety of Nexalin Therapy and to investigate the efficacy of Nexalin Therapy.
- Trial name
- NCT00774813
- Testing
- Nexalin 1.3mA Device, Nexalin 15mA device
- Where
- 2 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Kalaco Scientific, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-2 (NCT05550532)
- Testing
- Aticaprant
- Where
- 131 sites in United States, Argentina and 12 more
- Volunteers
- 444 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
- Trial name
- NCT00566202
- Testing
- Escitalopram, JNJ-18038683
- Where
- 26 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depression, Depression Moderate
Kintsugi Voice Device Pivotal Study
A prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06809907
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Depression
Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.
The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation
- Trial name
- NCT02981225
- Testing
- Phytostandard® Rhodiola-Saffron
- Where
- France
- Volunteers
- 59 people
- Sponsor
- PiLeJe